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ABSTRACT
Objective: To evaluate the frequency of JC polyomavirus (JCPyV) infection and anti-JCPyV anti-
bodies in patients with multiple sclerosis under natalizumab therapy.
Methods: Presence of anti-JCPyV antibodies and JCPyV DNA was analyzed in 39 patients with
relapsing-remitting multiple sclerosis undergoing natalizumab therapy. Anti-JCPyV antibodies
were evaluated in serum by a 2-step virus-like particle-based ELISA assay (Stratify), and JCPyV
DNA was evaluated in peripheral blood mononuclear cells, plasma, and urine by quantitative PCR.
The anti-JCPyV antibodies were evaluated in serum samples collected at the same time or later
than those collected for DNA analysis.
Results: JCPyV DNAwas detected in 59%of patients, and anti-JCPyV antibodies were present in
67%. JCPyV DNA occurred more often in blood than in urine. Anti-JCPyV antibodies were
observed in 70% of the JCPyV-infected patients, and JCPyV DNA was detected in 50% of
the patients without anti-JCPyV antibodies. When JCPyV DNA was investigated in blood and
urine the frequency of infection was higher than previously described.
Conclusion: Under these experimental conditions, with respect to the observed frequency of
JCPyV infection, the sensitivity of the anti-JCPyV antibody assay was lower than expected.
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GLOSSARY
Ab 5 antibody; JCPyV 5 JC polyomavirus; MAH 5 Marketing Authorization Holder; MS 5 multiple sclerosis; PBMC 5
peripheral blood mononuclear cells; PML 5 progressive multifocal leukoencephalopathy; RRMS 5 relapsing-remitting mul-
tiple sclerosis.
Progressive multifocal leukoencephalopathy (PML) caused by JC polyomavirus (JCPyV) reactiva-
tion is the most severe adverse event observed in patients with relapsing-remitting multiple sclerosis
(RRMS) treated with natalizumab.1 In order to predict PML risk, a biological marker of JCPyV
infection is needed. Because of the intermittent nature of JCPyV productive infection and because
JCPyV DNA detection by PCR assay may be elusive, the presence of anti-JCPyV antibodies (Abs)
seems to be a marker of infection that is more stable over time. Based on this assumption, an assay
that is highly sensitive and specific for the detection of anti-JCPyV Abs in serum (Stratify) was
developed.2 In addition, an algorithm based on this assay has been developed and validated for
PML risk stratification in patients with multiple sclerosis (MS) treated with natalizumab.3 How-
ever, the actual frequency of JCPyV-infected patients in MS patient populations is still controver-
sial, mainly because it depends on the JCPyV DNA identification method. Here the sensitivity of
the Stratify test in patients with MS was evaluated by comparing the frequency of anti-JCPyV Abs
with the frequency of JCPyV DNA in different body fluid compartments.
METHODS Patients. Paired blood and urine samples from 39 patients who were consecutively referred to the outpatient clinic of
the Regional Reference Center for Multiple Sclerosis of the Careggi University Hospital, Florence, Italy, were prospectively collected.
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The patients were recruited according to the following inclusion
criteria: definite diagnosis of MS; relapsing-remitting course;
fulfillment of the European Medicines Agency indications for
natalizumab administration in MS; and written informed
consent to participate in a program for PML risk stratification
established in collaboration with the Marketing Authorization
Holder (MAH) of natalizumab and based on a centralized anti-
JCPyV Ab assay in sera and on a locally organized JCPyV
DNA analysis in blood and urine. The results included in the
present study were generated by analyzing the diagnostic data
reported in the clinical records. The study was approved by the
local Ethic Committee (Comitato Etico Azienda Ospedaliero-
Universitaria Careggi, Largo Brambilla 3, Firenze) according to
the Italian law requirements (n. OSS 14.073). The authors
obtained preventive unrestricted permission for analyzing the
data provided by the MAH of the anti-JCPyV Ab assay.
JCPyV PCR quantification. The JCPyV DNA was extracted
from peripheral blood mononuclear cells (PBMC) obtained from
enriched buffy coats after density gradient separation of 8 mL of
whole blood, 200 mL of plasma, and 200 mL of urine, and was
quantified by JCPyV-specific real-time PCR targeting the large T
gene performed in triplicate using 100 ng of DNA (forward primer
59-GCAGCTTAGTGATTTTCTTAGG-39, reverse primer 59-
GAACACAGGTGTTTCCACCTGG-39, and TaqMan MGB
probe Fam-59-GGCACTGAATATTCATTCATGG39). Each
assay was carried out with negative controls (no template) and
DNA 10-fold dilutions (101–106 copies) of a plasmid carrying
the amplicon cloned (standard curve plot was 101–106 copies vs
36-21 cycle threshold). The lower limit of quantification of the
JCPyV DNA was 100 copies per mL of plasma and urine or per
mg of PBMC DNA.
JCPyV antibody assay. Anti-JCPyV Abs were detected in
serum by a 2-step virus-like particle-based ELISA assay
(Stratify, Focus Diagnostics, provided by Biogen Idec).4
Patients who tested positive for JCPyV DNA in blood or urine
but who had undetectable serum antibodies had their serum
samples retested for anti-JCPyV Abs.
RESULTS Demographic and clinical characteristics
and JCPyV infection status of the 39 patients with
RRMS are reported in table 1. The blood and urine
samples were collected biannually at baseline and during
the therapy, from July 2008 to September 2012. Pa-
tients received between 0 and 35 infusions and contrib-
uted between 1 and 8 samples. We included in the
study the first positive isolation of JCPyV DNA and
the anti-JCPyV Ab assay evaluated in the serum
sample of the same patient collected concurrently or
after the JCPyV DNA isolation. Eleven out of
39 samples included were collected at baseline, and
the other 28 were collected during natalizumab
administration. No obvious associations between
patient demographic and clinical characteristics (age,
sex, disease duration, previous treatments) and JCPyV
DNA status were observed. Overall, JCPyV DNA was
detected in at least one body fluid in 23 of 39 patients
(59%; table 2 and table e-1 at Neurology.org/nn): 17
patients (44%) had JCPyV DNA in PBMC, 4 patients
(10%) in plasma, and 13 patients (33%) in urine
(table 2). Of note, the assay could detect JCPyV
Table 1 Baseline demographic and clinical characteristics of the patients
according to JCPyV status
All patients
JCPyV DNA
positive
JCPyV DNA
negative
Total no. 39 23 16
Sex, F:M 30:9 18:5 12:4
Age
Mean 6 SD, y 37.8 6 9.2 35.9 6 7.9 40 6 10.1
Median, y 38 33 39.5
Disease duration
Mean 6 SD, y 11.6 6 5.8 11.1 6 5.0 12.2 6 6.5
Median, y 10 10 10.5
Previous treatments, n
IFN-b 37 21 16
Copolymer 9 6 3
Azathioprine 19 11 8
Mitoxantrone/cyclophosphamide 4 3 3
Abbreviations: IFN 5 interferon; JCPyV 5 JC polyomavirus.
Table 2 JCPyV DNA and anti-JCPyV Ab status in the patients with RRMS included in the study
Positive Negative Total Urine (copies/mL) Plasma (copies/mL) PBMC (copies/mg DNA)
JCPyV DNA statusa 23 (59%) 16 (41%) 39 13 (33%) 4 (10%) 17 (44%)
2 3 102–3 3 104 6 3 102–8 3 103 2 3 102–7 3 103
Anti-JCPyV Ab
Positive 16 9 25 (64%)
Negative 7 7 14 (36%)
Abbreviations: Ab 5 antibody; JCPyV 5 JC polyomavirus; PBMC 5 peripheral blood mononuclear cells; RRMS 5 relapsing-
remitting multiple sclerosis.
a The numbers represent the patients who tested positive for JCPyV DNA and/or for anti-JCPyV Ab presence. The range of
copy numbers obtained in urine, plasma, and PBMCs are also reported. The samples were collected every 6 months during
natalizumab therapy (from 0 to 38 infusions).
For the anti-JCPyV Ab assay, we used only the serum samples obtained at the same time or after those from the first
JCPyV DNA analysis that tested positive.
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DNA in 1 of 20 (5%) blood (PBMC or plasma)
samples and in 11 of 20 (55%) urine samples of
healthy donors. The range of viral load was similar in
the different compartments (table 2).
Anti-JCPyV Abs were present in 25 of 39 patients
included (64%) and in 16 of the 23 JCPyV-infected
patients (70%; table 2 and table e-1), indicating an
assay sensitivity of 0.7. In addition, JCPyV DNA was
present in 7 of the 14 anti-JCPyV antibody–negative
patients (50%; table 2), indicating that the negative
predictive value of the assay was 0.5. However, in this
context, the viral load observed in seronegative
patients did not differ from that observed in the sero-
positive patients. Of note, only 1 of the 7 patients
who was anti-JCPyV Ab–negative despite the pres-
ence of JCPyV DNA in PBMC showed seroconver-
sion in a sample taken within 6 months.
DISCUSSION In the present study, the frequency of
JCPyV DNA (59%) in patients with MS treated
with natalizumab was higher than that previously
reported when JCPyV infection was evaluated only
in urine (24%)2,5 and was consistent with that
reported when the infection was evaluated in
PBMC (60%).6
The high frequency of JCPyV in PBMC, a cell
compartment well-known for its ability to harbor
JCPyV-DNA, was not unexpected, particularly in
patients treated with natalizumab, considering the
effects of this drug on lymphoid precursor cells.7
The frequency of anti-JCPyV Abs observed in
serum (64%) was consistent with previous observa-
tions in similar populations.4,8 However, in our study,
anti-JCPyV Abs were present in only 70% of the 23
patients with JCPyV infection. This result puts the
sensitivity of the Stratify test at 70%, whereas in pre-
vious studies that used the same assay to detect anti-
JCPyV Abs sensitivity was reported to be 97%.4,9
This difference should probably be attributed to the
method of identifying the presence of the JCPyV
DNA, as the serologic data reported here and in pre-
vious studies2,4 have been obtained with the same
methods (the Stratify test). The previous data have
been obtained by testing the virus DNA only in
urine, whereas more recent data and the present study
indicate that when peripheral blood is also tested the
frequency of JCPyV DNA is higher than previously
described, particularly during natalizumab treat-
ment.7,9 In addition, the present study data, which
put the negative predictive value of the Ab assay at
50%, are consistent with other recent observations
reporting that when peripheral blood was included
in the analysis the false-negative rate of JCPyV serol-
ogy was 37%10 and 35%.9
The present results indicate that JCPyV DNA
evaluation in blood and urine could detect JC virus
infection earlier than anti-JCPyV Ab serology. Thus,
anti-JCPyV Ab serology may underestimate JCPyV
infection frequency, so it may be useful but not
always sufficient to predict PML risk. This possibility
points out the need to reevaluate the PML risk thus
far reported in anti-JCPyV seronegative patients
through additional virologic investigations.e1 How-
ever, the limited number of patients included does
not allow us to conclusively quantify the real fre-
quency of anti-JCPyV Ab–positive patients among
the JCPyV-infected patients with MS. This should
be reevaluated in a larger set of patients identified
by assessing JCPyV DNA in paired blood and urine
samples.
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